James C. Yao
YOU?
Author Swipe
View article: An Empirical Analysis of VLM-based OOD Detection: Mechanisms, Advantages, and Sensitivity
An Empirical Analysis of VLM-based OOD Detection: Mechanisms, Advantages, and Sensitivity Open
Vision-Language Models (VLMs), such as CLIP, have demonstrated remarkable zero-shot out-of-distribution (OOD) detection capabilities, vital for reliable AI systems. Despite this promising capability, a comprehensive understanding of (1) wh…
View article: Epidemiology of Neuroendocrine Neoplasms in the US
Epidemiology of Neuroendocrine Neoplasms in the US Open
Importance Neuroendocrine neoplasms (NENs) are increasing in incidence; prevalence and at the same time, practice patterns have also evolved, impacting classification and survival of these malignant neoplasms. However, updated epidemiologi…
View article: Supplementary Table S5 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Supplementary Table S5 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Supplementary Table S5. Adverse Events (All Grades).
View article: Supplementary Figure S1 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Supplementary Figure S1 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Supplementary Figure S1. Differentially expressed genes for according to PFS and OS (A), and immunologic genes with higher expression in association with prolonged PFS (B) and OS (C).
View article: Supplementary Table S4 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Supplementary Table S4 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Supplementary Table S4. Univariable Cox regression models for Overall survival.
View article: Supplementary Figure S3 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Supplementary Figure S3 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Supplementary Figure S3. Mutation prevalence in specified pathways for anal cancer (A);alterations noted in more commonly altered pathways (B).
View article: Supplementary Figure S4 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Supplementary Figure S4 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Supplementary Figure S4. Correlation of mRNA expression with copy number variation (A); genes associated with prolonged PFS and OS according to chromosome locus (B).
View article: Supplementary Table S1 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Supplementary Table S1 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Supplementary Table S1. Clinical features and biopsy analysis according to clinical outcome with study treatment for each participant.
View article: Supplementary Table S2 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Supplementary Table S2 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Supplementary Table S2. Study Representativeness Table.
View article: Supplementary Table S3 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Supplementary Table S3 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Supplementary Table S3. Univariable Cox regression models for Progression-free survival.
View article: Data from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Data from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Purpose:Anti–PD-L1 antibodies are associated with responses in <25% of patients with metastatic human papillomavirus–associated malignancies. VEGF signaling causes immune evasion and immune suppression within the tumor. We evaluated the an…
View article: Supplementary Figure S2 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Supplementary Figure S2 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Supplementary Figure S2. Total counts of mutation types among all pretreatment anal cancers (A); TMB per patient (B); median PFS (C) and OS (D) according to TMB status.
View article: Supplementary Figure S5 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Supplementary Figure S5 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Supplementary Figure S5. Unsupervised clustering according to SBS type (A); Kaplan Meier curves for PFS (B) and OS (C) according to cluster; PFS according to SBS31 signature level (D).
View article: Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2 Open
Background Fruquintinib is a highly selective, oral inhibitor of all 3 VEGF receptors. The global, randomized, double-blind phase 3 FRESCO-2 trial (NCT04322539) met its primary endpoint demonstrating significantly improved overall survival…
View article: Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Open
Purpose: Anti–PD-L1 antibodies are associated with responses in <25% of patients with metastatic human papillomavirus–associated malignancies. VEGF signaling causes immune evasion and immune suppression within the tumor. We evaluated th…
View article: Association between Remnant Cholesterol and All-Cause and Cardiovascular Mortality Risk in Chronic Kidney Disease Patients Over 60: A Cohort Study Based on NHANES 2001-2018
Association between Remnant Cholesterol and All-Cause and Cardiovascular Mortality Risk in Chronic Kidney Disease Patients Over 60: A Cohort Study Based on NHANES 2001-2018 Open
Objective Chronic kidney disease (CKD) patients face significant mortality risks, and remnant cholesterol (RC) may be a critical prognostic indicator. This study aimed to explore the association between RC and all-cause and cardiovascular …
View article: Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study Open
Fruquintinib delayed TTD of ECOG PS and did not negatively impact HRQoL versus placebo.
View article: Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma Open
Introduction Galectin-3 plays critical roles in the adhesion, proliferation, and differentiation of tumor cells. Recent data have suggested that galectin-3 plays a role in the development of hepatocellular carcinoma (HCC); however, its pro…
View article: Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab Open
BACKGROUND: Circulating tumor DNA (ctDNA) is a promising non-invasive marker for detection, diagnosis, treatment selection, and prognosis of hepatocellular carcinoma (HCC). OBJECTIVE: This study aimed to examine the utility of ctDNA as a p…
View article: Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma
Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma Open
Background The prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) is poor. Secondary brain metastasis (Br-M) occurs in less than 1% of patients. Clinical characteristics and molecular alterations have not been characterize…
View article: Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study
Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study Open
Efforts to improve the prognosis for patients with locally advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma have focused on neoadjuvant approaches to increase the pathological complete response (pathCR) rate, improve s…
View article: Editorial: New advancement in tumor microenvironment remodeling and cancer therapy
Editorial: New advancement in tumor microenvironment remodeling and cancer therapy Open
EDITORIAL article Front. Cell Dev. Biol., 07 March 2024Sec. Cancer Cell Biology Volume 12 - 2024 | https://doi.org/10.3389/fcell.2024.1384567
View article: Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma Open
Plasma GH is a prognostic biomarker in patients with advanced HCC treated with D+T. Given the relatively small patient cohort size, this finding should be further validated in larger randomized clinical trials in advanced HCC patients.
View article: Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features
Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features Open
Background Accurate prognostic stratification of hepatocellular carcinoma (HCC) is vital for clinical trial enrollment and treatment allocation. Multiple scoring systems have been created to predict patient survival, but no standardized sc…
View article: Financial Outcomes of “Bagging” Oncology Drugs Among Privately Insured Patients With Cancer
Financial Outcomes of “Bagging” Oncology Drugs Among Privately Insured Patients With Cancer Open
This cohort study examines the difference in per-patient per-month costs between drugs distributed under “bagging,” a drug delivery model that requires patients to obtain physician-administered medications via pharmacies, and traditional b…